Recently published international recommendations for use of SIR-Spheres®

  • Newest publication of its kind focused on Dosimetry
  • Fills a major information gap across international clinical communities
  • Support best practices to treat patients collaboratively in a program-based system to improve patient outcomes
  • Developed by 43 international and multidisciplinary experts, including 23 members of the steering committee

The SIR-Spheres Advantage empowers practitioners by providing programs and tools to implement these consensus recommendations


Recommendation 23: "For selective ablative treatments, its is recommended to consider a higher specific activity, hence a lower number of microspheres." (Strong consensus)

Recommendation 17: "SIRT should be conducted as soon as possible after the simulation [...]" (Strong consensus)

Recommendation 46: "Post-SIRT dosimetry is recommended" (Strong consensus) / R21-22: "A personlized approach, using dosimetry (partition model and/or voxel-based) is recommended for activity prescription" (Strong consensus)


Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Ok